HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone.

Abstract
Gallium nitrate is a potent antiresorptive drug that has been extensively tested in patients with accelerated bone turnover. We have evaluated the effects of this new agent in a pilot multicenter trial of 49 patients with advanced Paget's disease of bone. Patients were randomized to receive 0.05, 0.25, or 0.5 mg/kg.day gallium nitrate administered by sc injection in two 14-day cycles. Serum alkaline phosphatase, fasting 2-h urinary hydroxyproline and N- telopeptide collagen cross-links excretion, and quality of life were assessed every 2 weeks for 12 weeks. The group mean alkaline phosphatase activity at baseline was 854 +/- 100 (+/- SEM) IU/L. The mean changes from baseline to week 12 in serum alkaline phosphatase were +0.5%, -24%, and -31%, respectively, for the three doses tested. The differences for each of the higher dose levels (0.25 and 0.5 mg/kg.day) was statistically significant (P < or = 0.05), and nearly half of the patients treated with the 0.5 mg/kg.day dose achieved a 50% or more reduction in enzyme activity. The nadir value in hydroxyproline excretion occurred at 10 weeks, with mean changes of +9%, -10%, and -17% for the 0.05, 0.25, and 0.5 mg/kg.day doses, respectively; the difference was significant only at the 0.5 mg/kg.day level (P < 0.01). Urinary collagen cross-link excretion showed a significant decrease at the 0.25 and 0.5 mg/kg.day doses. We also observed a definite, but nonsignificant, trend for improved quality of life in patients treated at the highest drug dose. Minor discomfort at the injection site was frequently reported, but did not lead to interruption of therapy. Our results in these patients who had received moderate to extensive prior therapies with other drugs show that cyclical, low dose, sc administration of gallium nitrate is safe and effective for treating patients with advanced Paget's disease of bone.
AuthorsR S Bockman, F Wilhelm, E Siris, F Singer, A Chausmer, R Bitton, J Kotler, B J Bosco, D R Eyre, D Levenson
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 80 Issue 2 Pg. 595-602 (Feb 1995) ISSN: 0021-972X [Print] United States
PMID7852526 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Peptides
  • Creatinine
  • Gallium
  • Alkaline Phosphatase
  • Hydroxyproline
  • gallium nitrate
Topics
  • Adult
  • Aged
  • Alkaline Phosphatase (blood)
  • Bone Resorption (prevention & control)
  • Creatinine (urine)
  • Dose-Response Relationship, Drug
  • Female
  • Gallium (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Hydroxyproline (urine)
  • Male
  • Middle Aged
  • Osteitis Deformans (drug therapy, physiopathology)
  • Peptides (urine)
  • Prospective Studies
  • Quality of Life

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: